Veraxa Biotech AG (VRXA) News
Track canonical SquawkNews coverage tagged to VRXA, Veraxa Biotech AG. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 14 indexed stories across 8 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Veraxa Biotech appoints Raju Willener as CFO, effective immediately
Veraxa Biotech named Raju Willener as its chief financial officer, effective immediately. Willener succeeds Carl von Halem, who served as interim CFO after Torsten Burgermeister stepped down in July.
EQUITY | Sep 04, 2026, 11:18 AM UTC
L
Veraxa Biotech appoints Raju Willener as CFO
Veraxa Biotech AG appointed Raju Willener as Chief Financial Officer. The company says he brings more than three decades of global capital markets and corporate finance experience to support its BiTAC®-led pipeline.
EQUITY | Sep 04, 2026, 11:07 AM UTC
L
Veraxa Biotech appoints Raju Willener as chief financial officer
Veraxa Biotech appointed Raju Willener as chief financial officer.
EQUITY | Sep 04, 2026, 11:00 AM UTC
L
VRXA appoints Raju Willener as Chief Financial Officer
Veraxa Biotech appointed Raju Willener as Chief Financial Officer.
EQUITY | Sep 04, 2026, 11:00 AM UTC
L
Veraxa Biotech’s Secarna partnership milestone expands conjugation market potential
Veraxa Biotech says a Secarna partnership milestone opens a new potential market for conjugation technology.
EQUITY | Aug 28, 2026, 03:36 PM UTC
M
Veraxa Biotech, Secarna launch research collaboration on AOCs
Veraxa Biotech entered a strategic research collaboration with Secarna to develop antibody oligonucleotide conjugates for autoimmune and chronic immune diseases, with early in vitro work producing a candidate with higher
EQUITY | Aug 24, 2026, 11:03 AM UTC
L
Veraxa Biotech and Secarna reach research milestone in AOC alliance
Veraxa Biotech and Secarna Pharmaceuticals say they have achieved a research milestone in their antibody oligonucleotide conjugate alliance.
MNA | Aug 24, 2026, 11:00 AM UTC
M
VRXA Strengthens Patent Portfolio
VRXA expands patent portfolio
EQUITY | Jul 29, 2026, 11:00 AM UTC
L
VRXA - VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration w
VRXA - VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
EQUITY | Jul 27, 2026, 11:00 AM UTC
L
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Seer (NASDAQ: SEER ) stock moved upwards by 33.3% to $2.16 during Thursday's after-market session. The market value of their outstanding shares is at $89.6 million. Universe Pharmaceuticals (NASDAQ: UPC ) stock m
EQUITY | Jul 02, 2026, 09:05 PM UTC
L
Veraxa Biotech shares are trading higher after the company announced the initiation of cell line development for its lead BiTAC T-cell engag
Veraxa Biotech shares are trading higher after the company announced the initiation of cell line development for its lead BiTAC T-cell engager program.
EQUITY | Jul 02, 2026, 03:20 PM UTC
M
12 Health Care Stocks Move
Twelve health care stocks are moving in Wednesday's intraday session, with Pulsenmore and Icecure Medical leading the gainers and Aditxt and Atlantic International among the losers
EQUITY | Jun 24, 2026, 05:05 PM UTC
M
VRXA Expands R&D Hub
VERAXA Biotech expands its R&D hub in Heidelberg, increasing laboratory space by over 60% to accelerate clinical development of its BiTAC-TCE and ADC programs
EQUITY | Jun 24, 2026, 11:00 AM UTC
M
12 Health Care Stocks Move
Twelve health care stocks are moving in Tuesday's intraday session, with Aditxt and Atlantic International leading the gainers and Trinity Biotech and Tenon Medical leading the losers
EQUITY | Jun 23, 2026, 05:09 PM UTC